Sarepta raised to Outperform at Mizuho on strong results
Source: SeekingAlpha
2025-11-05 13:10:19 ET
More on Sarepta Therapeutics
- Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026
- FDA Duchenne Failure Hits Sarepta Amid 3Q25 Earnings Beat
- Sarepta Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation
- Sarepta plunges after late-stage Duchenne trial failure
- Elanco Animal Health set to join S&P MidCap 400, Sarepta to join S&P SmallCap 600
Read the full article on Seeking Alpha
For further details see:
Sarepta raised to Outperform at Mizuho on strong results
Sarepta Therapeutics Inc.
NASDAQ: SRPT
SRPT Trading
-0.63% G/L:
$16.565 Last:
134,073 Volume:
$16.50 Open:
SRPT Latest News
March 16, 2026 08:33:00 am
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
February 27, 2026 09:00:00 am
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
SRPT Stock Data
$1,921,797,010
96,823,361
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
